Patent US5847007A successfully refreshed from Google Patents.
US5847007A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
Assignee: Poniard Pharmaceuticals Inc
•
Filing: 1994-05-12
•
Granted: 1998-12-08
•
Expires: 2014-05-12
Abstract
Abstract TGF-beta activators and TGF-beta production stimulators are employed to maintain or increase vessel lumen diameter in a diseased or injured vessel of a mammal. Conditions such as restenosis following angioplasty, vascular bypass grafts, transplanted organs, atherosclerosis or hypertension are characterized by a reduced vessel lumen diameter. In a preferred embodiment of the invention, TGF-beta activators and production stimulators inhibit abnormal proliferation of smooth muscle cells. TGF-beta activators or production stimulators that are not characterized by an undesirable systemic toxicity profile at a prophylactic dose are also amenable to chronic use for prophylactic purposes with respect to disease states involving proliferation and/or migration of vascular smooth muscle cells over time. Further provided is a method for determining TGF-beta in vitro, thereby identifying a patient at risk for atherosclerosis and monitoring a recipient that has received one or more administrations of a TGF-beta activator or production stimulator.
Inventors
- 👤 David J. Grainger
- 👤 James C. Metcalfe
- 👤 Peter L. Weissberg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 21:37
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61K31/13; A61K31/135; A61K31/138; A61K31/33; A61K31/395; A61K31/40; A61P; A61P43/00; A61P7/00; A61P7/02; A61P9/00; A61P9/08; A61P9/10; A61P9/12; A61P9/14; C; C07; C07K; C07K14/00; C07K14/435; C07K14/705; C07K14/71; C07K16/00; C07K16/18; C07K16/22; C07K2317/00; C07K2317/70; C07K2317/73; C07K2317/74; G; G01; G01N; G01N2800/00; G01N2800/32; G01N2800/321; G01N2800/323
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
60 words
A method for preventing atherosclerosis in a mammal at risk therefor, or treating atherosclerosis in a mammal, which method comprises orally administering to the mammal the following: a dose of a therapeutic agent in an amount effective when administered orally to elevate the level of TGF-beta, wherein the increase in TGF-beta inhibits atherosclerotic lesion formation or development in the mammal.
Claim 2
Independent Claim
60 words
A method for preventing atherosclerosis in a mammal at risk therefor, or treating atherosclerosis in a mammal, which method comprises orally administering to the mammal the following: a dose of a therapeutic agent in an amount effective when administered orally to elevate the level of TGF-beta, wherein the increase in TGF-beta inhibits atherosclerotic lesion formation or development in the mammal.
Claim 3
Dependent Claim
12 words
The method of claim 1 wherein a series of doses are administered.
Claim 4
Dependent Claim
15 words
The method of claim 1 wherein the therapeutic agent inhibits lipid accumulation by the vessel.
Claim 5
Dependent Claim
17 words
The method of claim 1 wherein the therapeutic agent comprises trans-2- 4-(1,2-diphenyl-1-butenyl)phenoxy!-N,N-dimethyl-ethylamine, or a structural analog thereof.
Claim 6
Dependent Claim
16 words
The method of claim 4 wherein the therapeutic agent comprises a structural analog of trans-2- 4-(1,2-diphenyl-1-butenyl)phenoxy!-N,N-dimethyl-ethylamine.
Claim 7
Dependent Claim
12 words
The method of claim 1 wherein the therapeutic agent stabilizes atherosclerotic plaque.
Claim 8
Dependent Claim
20 words
The method of claim 1 wherein the therapeutic agent stimulates the production of TGF-beta mRNA or the expression of TGF-beta.
Claim 9
Dependent Claim
15 words
The method of claim 1 wherein the therapeutic agent cleaves the propeptide form of TGF-beta.
Claim 10
Dependent Claim
76 words
A therapeutic method comprising orally administering to a mammal an amount of a therapeutic agent effective upon oral administration to elevate the level of TGF-beta so as to treat a diseased blood vessel in said mammal, wherein said disease is associated with the diminution in the lumen volume of the diseased vessel, and wherein the therapeutic agent stabilizes atherosclerotic plaque, inhibits lipid accumulation, or inhibits or reduces diminution in vessel lumen diameter in the diseased vessel.
Claim 11
Dependent Claim
76 words
A therapeutic method comprising orally administering to a mammal an amount of a therapeutic agent effective upon oral administration to elevate the level of TGF-beta so as to treat a diseased blood vessel in said mammal, wherein said disease is associated with the diminution in the lumen volume of the diseased vessel, and wherein the therapeutic agent stabilizes atherosclerotic plaque, inhibits lipid accumulation, or inhibits or reduces diminution in vessel lumen diameter in the diseased vessel.
Claim 12
Dependent Claim
17 words
The method of claim 9 wherein a series of doses is administered over time to the mammal.
Claim 13
Dependent Claim
17 words
The method of claim 9 wherein the therapeutic agent comprises trans-2- 4-(1,2-diphenyl-1-butenyl)phenoxy!-N,N-dimethyl-ethylamine, or a structural analog thereof.
Claim 14
Dependent Claim
20 words
The method of claim 9 wherein the therapeutic agent stimulates the production of TGF-beta mRNA or the expression of TGF-beta.
Claim 15
Dependent Claim
16 words
The method of claim 9 wherein the therapeutic agent cleaves the propeptide form of the TGF-beta.
Claim 16
Dependent Claim
16 words
The method of claim 1 or 9 wherein the therapeutic agent increases the bioavailability of TGF-beta.
Claim 17
Dependent Claim
33 words
The method of claim 1 or 9 wherein the administration increases the level of active TGF-beta in said mammal relative to the level of active TGF-beta in said mammal prior to said administration.
Claim 18
Dependent Claim
33 words
The method of claim 1 or 9 wherein the administration increases the level of latent TGF-beta in said mammal relative to the level of latent TGF-beta in said mammal prior to said administration.
References Cited (Backward Citations)
US3010965A
Cited
US2914563A
Cited
US3168565A
Cited
US4536516A
Cited
US3288806A
Cited
US3634517A
Cited
US3940422A
Cited
US4070484A
Cited
USRE32944E
Cited
US4230862A
Cited
US4323707A
Cited
US4133814A
Cited
US4235988A
Cited
US4307111A
Cited
US5098903A
Cited
US5324736A
Cited
US4442119A
Cited
US5047431A
Cited
US4380635A
Cited
US4418068A
Cited
US5015666A
Cited
US4879315A
Cited
EP0095875B1
Cited
USRE33403E
Cited
US4696949A
Cited
US5491173A
Cited
US4996225A
Cited
US4512762A
Cited
US5226430A
Cited
US4824436A
Cited
US4826672A
Cited
US5316766A
Cited
US4859585A
Cited
US4962091A
Cited
EP0260066B1
Cited
US4839155A
Cited
US5120535A
Cited
US5075321A
Cited
US4973755A
Cited
US4835002A
Cited
US5221620A
Cited
US4929602A
Cited
US4997652A
Cited
US5468746A
Cited
US5213580A
Cited
US5208019A
Cited
US5393785A
Cited
US5395842A
Cited
US5340925A
Cited
US5268358A
Cited
US5304541A
Cited
US5380716A
Cited
US5032679A
Cited
US5364632A
Cited
US5026537A
Cited
US5242397A
Cited
US5112305A
Cited
US5043335A
Cited
US4990538A
Cited
US5049132A
Cited
US5328471A
Cited
US5166143A
Cited
US5140012A
Cited
US5189046A
Cited
US5189212A
Cited
US5192525A
Cited
US5219548A
Cited
US5238714A
Cited
US5053033A
Cited
US5180366A
Cited
US5362424A
Cited
US5308622A
Cited
US5171217A
Cited
US5280016A
Cited
US5254594A
Cited
US5116864A
Cited
US5213576A
Cited
US5296492A
Cited
US5216126A
Cited
US5185260A
Cited
US5270047A
Cited
US5238950A
Cited
US5326757A
Cited
US5480888A
Cited
US5354562A
Cited
US5346993A
Cited
US5280109A
Cited
US5444164A
Cited
US5288711A
Cited
US5283257A
Cited
US5393763A
Cited
US5457117A
Cited
US5385935A
Cited
US5354774A
Cited
US5308862A
Cited
US5453436A
Cited
US5482949A
Cited
US5445941A
Cited
US5354801A
Cited
US5441947A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-12-07 | 2002-06-08 | 2002-12-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-12-07 | 2006-06-08 | 2006-12-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-12-07 | 2010-06-08 | 2010-12-08 | $7700.00 | Window Closed / Lapsed |